Federal health officials have revived a contested change to the way drug discounts reach hospitals and clinics that serve low-income patients, setting a start date of January 1, 2027. Under the revised 340B Rebate Model Pilot Program, participating drug manufacturers would no longer give eligible providers a discounted purchase price at the point of sale. Instead, providers would pay the full price up front and claim a rebate afterward.
The Health Resources and Services Administration released the revised pilot at the end of July, and the notice appeared in the Federal Register days later. Manufacturers that want to take part must submit rebate plans by August 24, with approvals expected about a month afterward.
For patients, no prescription price changes on January 1. The stakes are indirect but real. The 340B program is how many community health centers, rural hospitals, HIV clinics and cancer centers pay for charity care, sliding-scale pharmacy services, patient navigators and free or reduced-cost medication programs. Those programs depend on predictable savings, and this change alters when the money shows up.
The Mechanics of Paying First and Collecting Later
Today, a covered entity buys a 340B drug at the discounted ceiling price directly. Under the pilot, the entity would order at the higher wholesale acquisition cost, submit a claim to the manufacturer, wait for the manufacturer to validate it, and then receive a rebate reflecting the discount. Rebates are to be calculated and paid at the drug-unit level.
HRSA argues the delay will be manageable. The agency wrote that "while many covered entities would need to place an order at the higher WAC price for the drugs included in the Pilot, payment to wholesalers for those orders, in most cases, would occur after the rebate from the manufacturer is received." Providers had warned during the comment period that cash-flow constraints, administrative costs and staffing demands would be substantial, and HRSA responded that some of those comments "generally assumed limited automation, manufacturer-specific reporting requirements, or ongoing parallel workflows that are not contemplated under the Pilot."
The scope is narrower than the program overall but broader than the first attempt. According to reporting by HFMA, the covered drugs are the roughly 25 selected for the Medicare Drug Price Negotiation Program for 2026 and 2027. That expands the pilot from 10 drugs and eight manufacturers to up to 25 products from 13 companies, which HRSA says represent less than 5.5 percent of total 340B sales.
The pilot is voluntary for manufacturers, is slated to run at least a year, and HRSA has committed to publishing an evaluation by the end of April 2028, with interim findings along the way.
A Second Attempt After a Court Blocked the First
This is not a new idea. The original version was scheduled to begin January 1, 2026, and was halted days before launch. As Becker's Hospital Review recounted, a Maine federal court blocked it after the American Hospital Association and the Maine Hospital Association sued, arguing the agency had violated the Administrative Procedure Act. The First Circuit declined to stay that order, the government dropped its appeal, and the court vacated the pilot and sent it back to HRSA.
The agency then sought public input from hospitals, health centers, manufacturers, pharmacies and patient advocates before releasing this version.
HRSA frames the redesign around oversight. The agency says claims-level verification would help prevent duplicate discounts already prohibited by statute, and points to rapid growth in the program: 340B purchases rose from $53.7 billion in 2022 to $66.3 billion in 2023 and $81.4 billion in 2024, roughly 50 percent growth in two years.
Hospital groups are not persuaded. Maureen Testoni, president and chief executive of 340B Health, said HRSA's first attempt was blocked by federal courts and may be again, adding that "the fundamental problem is that rebates are bad policy that will harm safety-net hospitals and the patients who depend on them."
Where the Squeeze Would Land Hardest
Not every 340B provider faces the same exposure. A large urban health system with substantial cash reserves can absorb a lag between purchase and rebate. A small rural hospital, a federally qualified health center or a Ryan White HIV clinic operating on thin margins cannot as easily float the difference on high-cost specialty drugs.
That distinction matters because 340B savings are not abstract institutional revenue. They commonly underwrite insulin and cancer drug assistance, medication-adherence programs, transportation help, behavioral health staffing and uninsured care. When those savings become slower or less certain, the programs funded by them are usually the first place administrators look for cuts.
There is also an administrative burden question. Submitting and reconciling claim-level data requires staff time and software many small providers do not have. HRSA has said the pilot assumes a more automated process than commenters described, and whether that assumption holds in practice is one of the open questions the pilot itself is meant to answer.
What Patients and Providers Should Watch Between Now and January
Nothing is settled. Manufacturer plans are due in late August and approvals are expected roughly a month later. Hospital associations have not ruled out returning to court, which means the January start date could again be disrupted.
Patients who rely on a community health center, rural hospital or HIV clinic for discounted medications do not need to take action now, and should not stop or change a prescription based on this announcement. If a clinic's medication assistance program changes next year, the practical step is to ask a pharmacist or patient navigator directly about alternatives, manufacturer assistance programs, and generic or biosimilar options.
Providers should watch for HRSA guidance on data submission requirements and evaluate cash-flow exposure on the specific drugs in the pilot. MedicalDaily will report on manufacturer participation once approvals are announced and on any renewed legal challenge.
Frequently Asked Questions
What is the 340B program? A federal program requiring drug manufacturers to sell covered outpatient drugs at discounted prices to eligible safety-net providers, including community health centers, rural hospitals and HIV clinics.
What is changing under the pilot? For a limited set of drugs, participating manufacturers would provide the discount as a rebate after a claim is validated, rather than as a lower purchase price up front.
When does it start? January 1, 2027. Manufacturers must submit rebate plans by August 24, 2026, with approvals expected the following month.
How many drugs are affected? Up to 25 products from as many as 13 manufacturers, which HRSA says represent less than 5.5 percent of total 340B sales.
Will my prescription cost more? Not directly. The change affects how providers are reimbursed, not the price a patient pays at the counter. The concern raised by hospital groups is that reduced or delayed savings could shrink the assistance programs those savings fund.
Could this be blocked again? Possibly. The first version was vacated by a federal court after a hospital lawsuit, and hospital groups have not ruled out further legal action.
What should I do if my clinic's drug assistance program changes? Talk to a pharmacist or patient navigator about manufacturer assistance programs, generic or biosimilar alternatives and other coverage options before changing any medication.
